There are 594 resources available
22P - Effects of datopotamab deruxtecan (Dato-DXd) vs docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): Results from TROPION-LUNG01
Presenter: Robin Cornelissen
Session: Poster Display session
23P - Early pembrolizumab clearance as a sensitive prognostic biomarker for survival in patients with advanced non-small cell lung cancer
Presenter: Rob Ter Heine
Session: Poster Display session
24P - 5-year real-world outcomes with first-line (1L) pembrolizumab plus (+) chemotherapy in advanced/metastatic NSCLC
Presenter: Vamsidhar Velcheti
Session: Poster Display session
25P - Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort
Presenter: Jie Hu
Session: Poster Display session
26P - Assessing first-line immunotherapy duration in advanced NSCLC
Presenter: Simone Rota
Session: Poster Display session
27P - Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis
Presenter: Sara Oresti
Session: Poster Display session
28P - Sex-based differences in the efficacy of PD-(L)1 inhibitors monotherapy for advanced non-small cell lung cancer: A meta-analysis of 13 phase III studies
Presenter: Thierry LANDRE
Session: Poster Display session
30P - Clinical characteristics and survival outcomes of long-term responders for advanced non-small cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: A multicenter retrospective study
Presenter: Zhijuan Du
Session: Poster Display session
31P - Camrelizumab plus chemotherapy as first-line treatment for advanced non-squamous NSCLC with brain metastases: Final overall survival results from the CAP-BRAIN trial
Presenter: Xue Hou
Session: Poster Display session